Sorafenib: all 509 studies that test it

Page 2 of 6. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung CancerTerminatedNCT00726986Phase 2Results posted
• Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor TherapyTerminatedNCT00722072Phase 2Results posted
• Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT00714948Phase 2Results posted
• Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic CancerCompletedNCT00696696Phase 2Results posted
• Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)CompletedNCT00692770Phase 3Results posted
• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00687674Phase 1Results posted
• A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.TerminatedNCT00678288Phase 2Results posted
• Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced MelanomaTerminatedNCT00673361Phase 2Results posted
• Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)CompletedNCT00661830Phase 2Results posted
• Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid CancerCompletedNCT00654238Phase 2Results posted
• Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLCCompletedNCT00647426Phase 2Results posted
• CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary CarcinomaCompletedNCT00634751Phase 1/2Results posted
• Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast CancerCompletedNCT00634634Phase 1/2Results posted
• A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast CancerTerminatedNCT00632541Phase 2Results posted
• Sorafenib Long Term Extension ProgramCompletedNCT00625378Phase 3Results posted
• Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast CancerTerminatedNCT00622466Phase 2Results posted
• Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00621686Phase 2Results posted
• The Effects of Sorafenib on Molecular Barrett's Esophagus CancerTerminatedNCT00619242Not applicableResults posted
• Sorafenib Dose Escalation in Renal Cell CarcinomaCompletedNCT00618982Phase 2Results posted
• Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine TumorsCompletedNCT00605566Phase 2Results posted
• Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable MelanomaCompletedNCT00602576Phase 2Results posted
• Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00600015Phase 2Results posted
• Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBMCompletedNCT00597493Phase 2Results posted
• PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney CancerTerminatedNCT00589550Phase 1Results posted
• Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone TherapyCompletedNCT00589420Phase 2Results posted
• Long-term Extension From RCC Phase II (11515)CompletedNCT00586495Phase 2Results posted
• Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)CompletedNCT00586105Phase 3Results posted
• Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCCTerminatedNCT00576056Phase 2Results posted
• Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast CancerTerminatedNCT00573755Phase 2Results posted
• Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XPCompletedNCT00565370Phase 1/2Results posted
• A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT00558636Phase 3Results posted
• Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell CarcinomaTerminatedNCT00557830Phase 2Results posted
• Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma MultiformeCompletedNCT00544817Phase 2Results posted
• Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast CancerCompletedNCT00544167Not applicableResults posted
• Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)CompletedNCT00542971Phase 1/2Results posted
• Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00536575Phase 1/2Results posted
• Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian CancerTerminatedNCT00526799Phase 1/2Results posted
• Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast CancerTerminatedNCT00525161Phase 2Results posted
• Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second RemissionTerminatedNCT00522301Phase 2Results posted
• Sorafenib in Myelodysplastic SyndromeTerminatedNCT00510289Phase 2Results posted
• Sorafenib in Treating Patients With Metastatic or Unresectable Kidney CancerTerminatedNCT00496756Phase 2Results posted
• Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)CompletedNCT00494299Phase 3Results posted
• 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) TherapyCompletedNCT00493636Phase 2Results posted
• A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT00492752Phase 3Results posted
• Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00474929Phase 1/2Results posted
• Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line SunitinibCompletedNCT00474786Phase 3Results posted
• Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate CancerCompletedNCT00466752Phase 2Results posted
• Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder CarcinomaCompletedNCT00461851Phase 2Results posted
• Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00454194Phase 2Results posted
• Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)TerminatedNCT00452387Phase 2Results posted
• A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00449033Phase 3Results posted
• Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00445588Phase 2Results posted
• Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal CancerCompletedNCT00436215Phase 2Results posted
• Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)CompletedNCT00424385Phase 1Results posted
• Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung CancerTerminatedNCT00417248Phase 1/2Results posted
• Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate CancerCompletedNCT00414388Phase 1/2Results posted
• BATTLE Program: Sorafenib in Patients With NSCLCCompletedNCT00411671Phase 2Results posted
• Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney CancerCompletedNCT00392821Phase 1/2Results posted
• Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian CancerCompletedNCT00390611Phase 2Results posted
• Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid CancerCompletedNCT00390325Phase 2Results posted
• Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT00387751Phase 2Results posted
• Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney CancerCompletedNCT00378703Phase 2Results posted
• Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the EyeCompletedNCT00329641Phase 2Results posted
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By SurgeryCompletedNCT00326898Phase 3Results posted
• BAY 43-9006 Plus Cetuximab to Treat Colorectal CancerCompletedNCT00326495Phase 2Results posted
• Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaTerminatedNCT00303966Phase 2Results posted
• A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT00300885Phase 3Results posted
• Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib MalateActive, not recruitingNCT00265798Phase 2Results posted
• Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT00253370Phase 2Results posted
• Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent SarcomaCompletedNCT00245102Phase 2Results posted
• Sorafenib in Treating Patients With Advanced or Recurrent Uterine CancerCompletedNCT00238121Phase 2Results posted
• S0505 Sorafenib in Treating Patients With Advanced Soft Tissue SarcomasCompletedNCT00217620Phase 2Results posted
• Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT00217399Phase 1/2Results posted
• Sorafenib in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00182689Phase 2Results posted
• Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's LymphomaCompletedNCT00131937Phase 2Results posted
• Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00131911Phase 2Results posted
• Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney CancerTerminatedNCT00126659Phase 2Results posted
• Sorafenib in Treating Patients With Advanced Anaplastic Thyroid CancerTerminatedNCT00126568Phase 2Results posted
• Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney CancerCompletedNCT00126503Phase 1/2Results posted
• Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney CancerCompletedNCT00121251Phase 1/2Results posted
• BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell CarcinomaCompletedNCT00117637Phase 2Results posted
• Sorafenib in Treating Patients With Regional or Metastatic Cancer of the UrotheliumTerminatedNCT00112905Phase 2Results posted
• Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary TractCompletedNCT00112671Phase 2Results posted
• A Treatment Combination for Patients With Unresectable Stage III or Stage IV MelanomaCompletedNCT00111007Phase 3Results posted
• Treatment for Subjects With Unresectable Stage III or Stage IV MelanomaCompletedNCT00110994Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00110019Phase 3Results posted
• A Research Study to Treat Patients With Advanced Hepatocellular CarcinomaCompletedNCT00108953Phase 2Results posted
• A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT00105443Phase 3Results posted
• BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)CompletedNCT00101413Phase 2Results posted
• BAY43-9006 - Phase II in Advanced Breast CancerCompletedNCT00101400Phase 2Results posted
• BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung CancerCompletedNCT00098254Phase 2Results posted
• A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate CancerCompletedNCT00090545Phase 2Results posted
• Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell CancerCompletedNCT00073307Phase 3Results posted
• Sorafenib in Treating Patients With Refractory Non-Small Cell Lung CancerCompletedNCT00064350Phase 2Results posted
• A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular CarcinomaCompletedNCT00044512Phase 2Results posted
• A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute LeukemiasWithdrawnNCT06474663Phase 1
• Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.CompletedNCT06030895Not applicable
• Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AMLStatus unknownNCT05404516Phase 2
• Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT StudyCompletedNCT05117957Phase 2
• TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCCStatus unknownNCT04992143Phase 2

← Sorafenib overview